[Ip-health] US Medicine Price Trends
Sean Michael Flynn
sflynn at wcl.american.edu
Tue Oct 28 12:07:20 PDT 2014
This report was shared recently by Paul Davis.
"The median revenue per patient of the Top 100 drugs has increased from
$1,260 in 2010 to $9,400 in 2014, representing an seven-fold increase (see
"There are now seven treatments priced in excess of $100,000 per patient per
year in 2014, versus four in 2010."
³We found that 19 drugs in the Top 100 have moved up a price bracket in the
last four years (see page: 7). E.g., nine products have gone from costing
less than a $1,000 in 2010 to being priced in the $1,000 to $5,000 bracket
³The US phenomenon of drug price inflation - where prices increase after
initial launch - is in direct opposition to Japan where the government
reimbursement system reduces the price of successful products which beat
initial sales expectations at launch.²
"The biggest concern is that with government drug spend approaching 43% of
the USA market by 2017, up from 24% in 2005, the system lacks enough
automatic discounts off the private price, and safeguards against drug price
rises from companies, to be sustainable. This is particularly an issue for
Medicare Part B and Part D programs. The expansion of Medicare (2005+) and
Medicaid (2014+) enrolment has incrementally expanded the USA drug market,
so any discounts off private drug prices will act only to moderate growth.
Thus the call
for reform will grow stronger."
More information about the Ip-health